Bispecific Antibody Combinations In Relapsed Refractory Multiple Myeloma: TRIMM-2 Study

Opinion
Video

Panelists discuss how the TRIMM-2 study explores the potential of combining bispecific antibodies to enhance treatment efficacy in patients with relapsed/refractory multiple myeloma, potentially offering a novel therapeutic strategy for this difficult-to-treat condition.

Recent Videos
9 Experts are featured in this series.
9 Experts are featured in this series.
2 experts are featured in this series.
9 Experts are featured in this series.
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
Related Content